A similar study in non-small cell lung cancer also showed a better response rate to platinum-based ICT in patients with higher CD8+/FOXP3+ ratios (both in adenocarcinomas and squamous cell carcinomas), although CD8+ TIL infiltration was only associated with the response to ICT in adenocarcinomas [34]. The gene discussed is FOXP3; the disease is non-small cell lung carcinoma.